Is your company moving toward risk-based monitoring of clinical trials as recommended by the FDA? Are you concerned about the integrity and quality of your clinical trials data? Can you tell the difference between bad data and fraud? Richard Zink’s new book Risk-Based Monitoring and Fraud Detection in Clinical Trials Using JMP® and SAS® presents a practical approach for centralized monitoring of clinical trials using JMP Clinical software.
In chapter 4, "Detecting Fraud at the Clinical Site," Zink presents specific examples and explores graphical and statistical approaches for identifying both site- and patient-perpetrated fraud.
Ultimately, says Zink, “A proactive, risk-based approach to quality in clinical trials will more effectively protect the individuals participating in clinical trials.”